MedTrace Logo

Evaluation of Compliance With Treatment by Genvoya in HIV Post-exposure Prophylaxis

NCT02998320 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2019-02-15

No results posted yet for this study

Summary

This study measures the proportion of enrolled patients taking the uninterrupted HIV post-exposure prophylaxis Genvoya for four weeks

Conditions

  • HIV Risk

Interventions

DRUG

Genvoya

Oral use (one tablet each day); 150/150/200/10 mg; 28 days

Sponsors & Collaborators

  • Gilead Sciences

    collaborator INDUSTRY

  • Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux

    lead NETWORK

Principal Investigators

  • David Rey · Hôpitaux Universitaires de Strasbourg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-10
Primary Completion
2018-06-30
Completion
2018-09-30

Countries

  • France

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02998320 on ClinicalTrials.gov